The Aptamer Therapeutics Company™
Confidential
Preclinical Safety Assessment of Aptamer Therapeutics
Scott A. Barros, PhD, DABTSr. Scientist, Toxicology
2Confidential
apto: “to fit”
mer: “smallest unit of repeating structure”
What is an Aptamer?
Aptamers are single stranded folded oligonucleotides that bind to molecular (protein) targets with high affinity and specificity
3Confidential
Aptamer Structure
Nature Structural Biology, 7(1):53-57
• Unique tertiary structures allow aptamers to fold into stable scaffolds for carrying out molecular recognition
• van der Waals, hydrogen bonding, and electrostatic interactions drive high affinity target binding
• Designed to block protein-protein interactions
• Share properties of both small molecules and biologics
• SELEX (Systematic Evolution of Ligands by Exponential Enrichment)Tuerk and Gold (1990) Science 249, p505-510
4Confidential
Medicinal Chemistry Process
2’-deoxy 2’-OMe
O
OMe
BO
O
O
-OP
H3C
P=O P-Me2’-OMe 2’-deoxy
O
H
BO
O
O
P
P=O P=S
O
OCH3
BO
O
S
-OP
0
0.2
0.4
0.6
0.8
1
0.001 0.01 0.1 1 10 100
Binding affinity measurement
Fract
ion a
pta
mer
bound
[target] nM
beneficial
tolerated
• Increased plasma stability• Increased affinity• Increased potency
• Proprietary processes• Multiple chemistries employed
●●●●●●●●●●
● ● ● ● ● ●●
●●
●●●●●●●●
●
●●●●●●●●●●
● ● ● ● ● ●●
●●
●●●●●●●●
●
●●●●●●●●●●
● ● ● ● ● ●●
●●
●●●●●●●●
●
●●●●●●●●●●
● ● ● ● ● ●●
●●
●●●●●●●●
●
1 2 N
singlesubstitutions,nucleotide A
composites
●●●●●●●●●●
● ● ● ● ● ●●
●●
●●●●●●●●
●
3
singlesubstitutions,
nucleotide B, etc composites
early lead optimized lead
● ● ● ●
5Confidential
In general, aptamers have toxicological properties similar to other oligonucleotide therapeutics, but with a few modality-specific considerations:
• The diversity and combinations of chemical compositions employed distinguish aptamers from other oligonucleotide therapeutic modalities
―15-40 mer, with variety of stabilizing 2’ ribose modifications and 3’-idT―Often with large molecular weight PEG conjugate
• Species restriction and pharmacological activity―Species restriction is often observed; similar to mAbs―Two species toxicology testing, typically rat (off-target species) and
monkey (on-target species)
• Our goal is to keep aptamer at the site of action in the plasma and interstitial tissue compartments, outside of cells
―Plasma concentration and plasma exposure is more of a focal point than tissue concentrations
• Dose regimens vary widely depending on the aptamer compositions and the intended use
―IV bolus, infusion, repeated bolus, SC bolus, etc.
Considerations in Safety Assessment of Aptamers
6Confidential
Discovery Toxicology
Purpose of Discovery Toxicology:• To detect potential development-limiting toxicological liabilities as early as
possible and avoid or engineer them out
Discovery Toxicology for Aptamers:• Thus far, the general toxicological properties of aptamer therapeutics have
been mostly predictable, class-based, and with good safety margins for the intended uses
―Therefore, we do not consider in vivo discovery toxicology important since we would only expect to find the predictable outcomes (discussed later)
• But, we do not fully understand what attributes modulate the occurrence or potency of the known class-based effects (not yet fully predictable)
―Therefore, we screen in vitro for oligo class-based toxicities during lead optimization in order to detect early and engineer if necessary
• These in vitro screening assays include:―Anti-coagulation – Polyanion effect, sequence independent, influenced by
composition―Complement activation – Polyanion effect, sequence independent,
influenced by composition―Immune Stimulation – Sequence dependent, influenced by composition
(TLRs)
7Confidential
In vitro Complement Activation
Assay method:• Add aptamer or control oligo to
human serum or blood anti-coagulated with direct thrombin inhibitor
• Incubate 37°C, 30 min• Quench complement reaction with
EDTA• Assay for generation of C3a or C5a
split products
Oligonucleotides, especially phosphorothioate oligos, can stimulate complement activation via Factor H or other mechanisms
0
25
50
75
0 10 20 30
PEG-aptameraptamer, no PEGthio-aptamerantisense oligo
[C5
a]
ng/m
L
[oligonucleotide] M
8Confidential
In vitro Anticoagulation
Assay method:• Add aptamer or control oligo to
citrated human plasma• Add aPTT reagent and calcium, and
measure time to clot
Oligonucleotides, especially phosphorothiate oligos, inhibit coagulation, likely via intrinsic tenase complex (factors IXa and VIIIa, phospholipids, calcium)
0
60
120
180
240
300
0 10 20 30
PEG-aptameraptamer, no PEGthio-aptamerantisense oligo
aPTT,
seco
nds
[oligonucleotide] M
9Confidential
In vitro Immune Stimulation Screens
• Cytokine release and proliferation assays measure TLR 3,7/8,9 activation• CpG oligonucleotides and transfected immunostimulatory RNAs induce
PBMC/mouse splenocytes to produce IL-6 and interferon alpha• Class A and C type CpGs induce PBMCs and mouse splenocytes to proliferate
ARCxxx
IL-6 release from PBMCs
0
200
400
600
800
1000
1200
1400
1600
1800
2000
1 10 100 1000
nM ODN
pg
/mL
IL
-6 ARCxxx
ARCyyy
ARCzzz
CpG-B
10Confidential
Secondary Pharmacology
• “Off-target” protein interactions with ASOs have been referred to as “aptamer effects”
• All oligonucleotides can have relatively low affinity interactions with unintended target proteins (polyanion effects)
• This is to be distinguished from a therapeutic aptamer which has been selected and optimized for high potency interactions with a target protein
• These “off-target” effects can manifest as secondary pharmacology, at some concentration
• How do we test for secondary pharmacology?―Directed specificity testing depending on the target protein―Discovery in vitro toxicology screens (C’ activation, anti-
coagulation, immune stimulation)―Receptor/enzyme panel screens―In vivo safety pharmacology and general toxicology
11Confidential
Safety Pharmacology
• We adhere to the principles of ICH S7a―CNS:
Standard CNS study in rats―CV
hERG patch clamp Telemetered cynomolgus monkey in vivo study
―Respiratory: Respiratory endpoints incorporated into cynomolgus monkey
CV study
• We have seen no significant test article related effects in these studies to date
12Confidential
Genetic Toxicology
• We have conducted standard ICH battery of genetic toxicity studies―Ames assay―Human HPBL chromosomal aberrations―In vivo micronucleus (rat)
• We have tested the final development compound in these assays (e.g., PEGylated) using standard practice for dose selections
• All results have been negative for genotoxic effects
13Confidential
General Toxicology - Principles
• Species selection:―We conduct two species general toxicology testing―Rodents often non-pharmacologically responsive “off-target” species―Monkeys generally pharmacologically responsive “on-target and off-
target species”
• Route and regimens appropriate for the intended clinical use―Can vary widely (IV bolus, infusion, SC bolus; continuous, daily,
weekly, etc)―Have successfully used single-dose toxicology to support single dose
in man―Repeated-dose designs may mimic those for mAbs when PEGylated
aptamer has long half-life (e.g., twice weekly dosing, etc)
• Dose selection―Clinical equivalent (low), max feasible or chosen multiple of human
(high), and log mean (mid), based on plasma exposure multiples―Clinically-relevant dose range is generally similar to what is seen with
mAbs―We generally express dose on basis of aptamer mass, exclusive of
PEG; PEG doses are generally 3-4X aptamer doses
14Confidential
Typical Findings in General Toxicology Studies
1. Exaggerated pharmacology• Expected based on target biology
2. Anticoagulation• Generally a modest effect with good safety margins
3. C’ activation• Rarely seen and only at very high concentrations with aptamers
tested to date
4. Bone marrow suppression• Seen in repeated-dose toxicity studies, modest effect with good
safety margins
5. Hemodilution (PEGylated oligos only)• Osmotic properties of PEG at high plasma concentrations
6. Basophilic granulation and/or vacuolization• Mononuclear phagocytes and kidney tubule epithelial cells• Presence of drug-related material in these specific cells
15Confidential
Exaggerated pharmacology
No spontaneous bleeding despite <3% vWF activity and prolonged cutaneous bleeding times, even at 25X projected human effective dose
Single-dose, 4-hour Infusion
0.1
1
10
100
1000
0 1 4
4.2
5
4.5 5 8
12
16
28
52
76
Hours Post-dose
AR
C1
77
9 (
ug
oli
go
/mL
)v
WF
Ac
tiv
ity
(%
)
0
4
8
12
16
CB
T (
min
)
Dosing
Conc., Control
Conc., 25 mg/kg
Activity, Control
Activity, 25 mg/kg
CBT, Control
CBT, 25 mg/kg
Cynomolgus Monkey
16Confidential
Anticoagulation
Concentration-dependent prolongation of aPTT
Single-dose, 4-hour Infusion
0.1
1
10
100
1000
0 1 4
4.2
5
4.5 5 8
12
16
28
52
76
10
0
16
8
34
0Hours Post-dose
20
K P
EG
-ap
tam
er
(ug
oli
go
/mL
)
25
35
45
55
65
75
aP
TT
(s
ec
)
Dosing
Conc., Control
Conc., 3 ug/kg/min (1 mg/kg)
Conc. 15 ug/kg/min (5 mg/kg)
Conc., 75 ug/kg/min (25 mg/kg)
aPTT, Control
aPTT, 75 ug/kg/min (25 mg/kg)
aPTT, 3 ug/kg/min (1 mg/kg)
aPTT 15 ug/kg/min (5 mg/kg)
Cynomolgus Monkey
17Confidential
Complement Activation Dose-, Rate-, Concentration-Dependent
Threshold for Bb elevation:~50 µg P=S ASO/mL, ~300 µg DNA aptamer/mL
Henry, JPET 1997, 281:810-816
Single-dose, 4-hour Infusion
0
1
2
3
4
5
6
7
0.01 0.1 1 10 100 1000 10000
DNA Aptamer Conc. (ug/mL)
Bb
Co
nc
(ug
/mL
)
Control 0.5 mg/kg/min (120 mg/kg)
2.5 mg/kg/min (600 mg/kg) 10 mg/kg/min (2400 mg/kg)
7-day Repeated-dose, 6-hour Infusion
0
1
2
3
4
5
6
7
0.01 0.1 1 10 100 1000 10000
DNA Aptamer Conc (ug/mL)
Bb
Co
nc
(ug
/mL
)
Control 0.5 mg/kg/min (180 mg/kg/day)
1 mg/kg/min (360 mg/kg/day) 2.5 mg/kg/min (900 mg/kg/day)
Repeated-dose, Dose-escalating, 4-hour Infusion
0
1
2
3
4
5
6
7
0.01 0.1 1 10 100 1000 10000
DNA Aptamer Conc (ug/mL)
Bb
Co
nc
(ug
/mL
)
Control 0.5 mg/kg/min (120 mg/kg)
1.5 mg/kg/min (360 mg/kg) 5 mg/kg/min (600 mg/kg)
10 mg/kg/min (2400 mg/kg)
Cynomolgus Monkeys
18Confidential
Bone marrow suppression
Lower hemoglobin and reticulocyte counts after 14-day repeated-dose in rats
11
11.5
12
12.5
13
13.5
Hgb (g/dL)
0
50
100
150
200
250
aRetic (x10^9/L)
42K PEG Control, 750 mg PEG/kg
40K PEG-aptamer, 5 mg oligo/kg
40K PEG-aptamer, 15 mg oligo/kg
40K PEG-aptamer, 50 mg oligo/kg
40K PEG-aptamer, 150 mg oligo/kg
Sprague-Dawley Rat; Subcutaneous bolus, 3x/week for two weeks
19Confidential
7-day Continuous Infusion
0.1
1
10
100
1000
10000
00
.5 24
48
96
16
81
68
16
91
69
17
21
76
18
01
92
21
62
40
26
42
88
31
23
36
50
4
Hours Post-dose
40
K P
EG
-ap
tam
er
(ug
oli
go
/mL
)
0
2
4
6
8
10
To
tal
Pro
tein
(g
/dL
)
Dosing
13 ug/kg/min (141 mg/kg)
39 ug/kg/min (423 mg/kg)
130 ug/kg/min (1410 mg/kg)
TP, 0 mg/kg
TP, 141 mg/kg
TP, 423 mg/kg
TP, 1410 mg/kg
Hemodilution; PEG-Associated Plasma Volume Expansion
Other parameters comparably affected included:alb, glob, ALT, LD, ALP, GGT, chol, trig, RBC, Hgb, Hct, retic, WBC, neut, lymph, plat
PEG doses and concentrations are 4X oligo
Cynomolgus Monkey
20Confidential
Basophilic granulation and/or vacuolization, mostly in mononuclear phagocytes
Liver; Kupffer cell vacuolizationSpleen; PAMS vacuolization
Kidney; Basophilic granules in proximal tubulular epithelium
• Presence of test article-related material in cells has not been associated with apparent adverse effects on those cells or tissues.
• Therefore, we have not considered this finding alone to be an adverse effect.
21Confidential
Additional Toxicology Testing
• We plan to do standard ICH-guided testing for reproductive toxicology, chronic toxicology and carcinogenicity, when appropriate
• We desire to test in at least 1 pharmacologically active species whenever possible
• We do not propose to use surrogate molecules in toxicology testing (surrogate molecules would always differ appreciably in sequence, composition, potency, specificity, etc.)
22Confidential
Conclusions
• Aptamers share many “class- based” properties with other oligonucleotides
• But aptamers also differ appreciably from other oligonucleotides in both MOA and chemical compositions
• We have developed a customized toxicology testing strategy for aptamers
• The toxicities we have seen are class-based, as seen with other oligonucleotides or with other PEGylated macromolecules
• The aptamers tested to date have shown good safety margins between efficacious dose and concentrations and NOAELs in toxicology studies
23Confidential
The Archemix Gang